|Calculated MW||50219 Da|
|Homology||Mouse, rat - 15/16 amino acid residues identical.|
|Other Names||Equilibrative nucleoside transporter 1, Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter, Equilibrative NBMPR-sensitive nucleoside transporter, Nucleoside transporter, es-type, Solute carrier family 29 member 1, SLC29A1, ENT1|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)EQETKLDLISKGEEPR, corresponding to amino acid residues 245-260 of human Equilibrative Nucleoside Transporter 1 (Accession Q99808). Intracellular, 3rd loop.|
|Peptide Confirmation||Confirmed by mass-spectrography and amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl DDW.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Nucleosides play other important roles beyond their nucleic acid synthesis building block role. For example, they are involved in energy metabolism; they serve as ligands of purinergic receptors and act as influential signaling molecules1. Being hydrophilic, nucleosides cannot simply diffuse across the plasma membrane in order to exert their various functions, but rather need to be physically transported via nucleoside transporters1,2. Two different transporter families are responsible for transporting nucleosides across the plasma membrane: The Concentrative Nucleoside Transporter proteins (CNT, SLC28 family), which consist of three members, CNT1-3, and act as Na+-dependent symporters1,3. The Equilibrative Nucleoside Transporter proteins ENT1-4 (ENT, SLC29 family), which mediate a Na+-independent facilitated diffusion. Therefore, ENTs act as bidirectional carriers, responsible for the influx and efflux of substrates1. Structurally, ENT transporters have eleven transmembrane domains with an intracellular N-terminal and an extracellular C-terminal1. The best characterized ENT transporters are ENT1 and ENT2, which although display a broader range of substrate selectivity, have lower affinities for nucleosides compared to concentrative transporters. They are ubiquitously expressed, for example ENT1 is expressed in erythrocytes, vascular endothelium, placenta, brain, heart, liver and colon1,4. ENT2 displays more or less the same expression pattern but in addition, is strongly expressed in skeletal muscle1,5. ENT3 is a lysosomal pH-dependent transporter capable of transporting adenine, and ENT4 also transports adenine at acidic pH. They are also broadly expressed with ENT3 displaying high expression in the placenta and ENT4 in the heart6,7. As mentioned above, nucleosides have a variety of cellular/physiological functions suggesting that transporters responsible for their trafficking may also have functional attributes. Indeed, ENT1 plays a role in proliferation and therefore is responsible for the constitutive trafficking of nucleosides1. There is no evidence that nucleoside transporters are directly involved in pathophysiologies, but they are clinically significant. For example, nucleoside transporters are responsible for the cellular uptake of a number of nucleoside-derived anticancer drugs1. Abgent is pleased to offer a highly specific antibody directed against an epitope of human Equilibrative Nucleoside Transporter 1. Anti-Equilibrative Nucleoside Transporter 1 (ENT1) antibody (#AG1165) can be used in western blot analysis and immunohistochemistry applications and was specifically designed to recognize rat, mouse and human ENT1.
References 1. Molina-Arcas, M. et al. (2009) Curr. Vasc. Pharmacol. 7, 426. 2. Rose, J.B. and Coe, I.R. (2008) Physiology 23, 41. 3. Baldwin, S.A. et al. (2004) Pflugers Arch. 447, 735. 4. Pennycooke, M. et al. (2001) Biochem. Biophys. Res. Commun. 280, 951. 5. Crawford, C.R. et al. (1998) J. Biol. Chem. 273, 288. 6. Baldwin, S.A. et al. (2005) J. Biol. Chem. 280, 15880. 7. Barnes, K. (2006) Circ. Res. 99, 510.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.